CN1129580C - 结晶四氢吡啶衍生物的方法及所得晶形 - Google Patents

结晶四氢吡啶衍生物的方法及所得晶形 Download PDF

Info

Publication number
CN1129580C
CN1129580C CN97180863A CN97180863A CN1129580C CN 1129580 C CN1129580 C CN 1129580C CN 97180863 A CN97180863 A CN 97180863A CN 97180863 A CN97180863 A CN 97180863A CN 1129580 C CN1129580 C CN 1129580C
Authority
CN
China
Prior art keywords
mixture
ethyl
type
naphthyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97180863A
Other languages
English (en)
Chinese (zh)
Other versions
CN1241180A (zh
Inventor
A·卡隆
B·法兰克
O·莫尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of CN1241180A publication Critical patent/CN1241180A/zh
Application granted granted Critical
Publication of CN1129580C publication Critical patent/CN1129580C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN97180863A 1996-12-23 1997-12-23 结晶四氢吡啶衍生物的方法及所得晶形 Expired - Fee Related CN1129580C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR96/15904 1996-12-23
FR9615904A FR2757543B1 (fr) 1996-12-23 1996-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (2)

Publication Number Publication Date
CN1241180A CN1241180A (zh) 2000-01-12
CN1129580C true CN1129580C (zh) 2003-12-03

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97180863A Expired - Fee Related CN1129580C (zh) 1996-12-23 1997-12-23 结晶四氢吡啶衍生物的方法及所得晶形

Country Status (38)

Country Link
EP (1) EP0950050B1 (cg-RX-API-DMAC7.html)
JP (2) JP4499188B2 (cg-RX-API-DMAC7.html)
KR (1) KR100586670B1 (cg-RX-API-DMAC7.html)
CN (1) CN1129580C (cg-RX-API-DMAC7.html)
AR (1) AR009672A1 (cg-RX-API-DMAC7.html)
AT (1) ATE307802T1 (cg-RX-API-DMAC7.html)
AU (1) AU736697B2 (cg-RX-API-DMAC7.html)
BR (1) BR9714081A (cg-RX-API-DMAC7.html)
CA (1) CA2275596C (cg-RX-API-DMAC7.html)
CO (1) CO5070688A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ296689B6 (cg-RX-API-DMAC7.html)
DE (1) DE69734460T2 (cg-RX-API-DMAC7.html)
DK (1) DK0950050T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ2383A1 (cg-RX-API-DMAC7.html)
EE (1) EE04188B1 (cg-RX-API-DMAC7.html)
EG (1) EG21567A (cg-RX-API-DMAC7.html)
ES (1) ES2251038T3 (cg-RX-API-DMAC7.html)
FR (1) FR2757543B1 (cg-RX-API-DMAC7.html)
HR (1) HRP970699B1 (cg-RX-API-DMAC7.html)
HU (1) HU227425B1 (cg-RX-API-DMAC7.html)
IL (1) IL129938A (cg-RX-API-DMAC7.html)
IN (1) IN186976B (cg-RX-API-DMAC7.html)
IS (1) IS2357B (cg-RX-API-DMAC7.html)
MY (1) MY118015A (cg-RX-API-DMAC7.html)
NO (1) NO312364B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ336130A (cg-RX-API-DMAC7.html)
PL (1) PL190494B1 (cg-RX-API-DMAC7.html)
RS (1) RS49882B (cg-RX-API-DMAC7.html)
RU (1) RU2192416C2 (cg-RX-API-DMAC7.html)
SA (1) SA98180971B1 (cg-RX-API-DMAC7.html)
SI (1) SI0950050T1 (cg-RX-API-DMAC7.html)
SK (1) SK285088B6 (cg-RX-API-DMAC7.html)
TR (1) TR199901363T2 (cg-RX-API-DMAC7.html)
TW (1) TW518322B (cg-RX-API-DMAC7.html)
UA (1) UA60324C2 (cg-RX-API-DMAC7.html)
UY (1) UY24825A1 (cg-RX-API-DMAC7.html)
WO (1) WO1998028271A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA9711576B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
WO2011111855A1 (ja) 2010-03-12 2011-09-15 株式会社日本触媒 吸水性樹脂の製造方法
JP5870183B2 (ja) * 2011-04-15 2016-02-24 エムキュア ファーマシューティカルズ リミテッド リルピビリン中間体の合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521428A (en) * 1982-08-16 1985-06-04 Sanofi Anorexigenic trifluoromethylphenyltetrahydropyridines and pharmaceutical compositions containing them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521428A (en) * 1982-08-16 1985-06-04 Sanofi Anorexigenic trifluoromethylphenyltetrahydropyridines and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
PL334256A1 (en) 2000-02-14
HUP0001387A2 (hu) 2000-09-28
CA2275596C (en) 2005-10-11
EG21567A (en) 2001-12-31
KR100586670B1 (ko) 2006-06-07
TW518322B (en) 2003-01-21
PL190494B1 (pl) 2005-12-30
DE69734460D1 (de) 2005-12-01
EP0950050A1 (fr) 1999-10-20
NO993076D0 (no) 1999-06-22
AU5668498A (en) 1998-07-17
JP4499188B2 (ja) 2010-07-07
IL129938A (en) 2004-06-20
FR2757543B1 (fr) 1999-04-02
FR2757543A1 (fr) 1998-06-26
AR009672A1 (es) 2000-04-26
EE9900264A (et) 2000-02-15
UY24825A1 (es) 1998-04-21
SA98180971B1 (ar) 2006-09-13
HU227425B1 (en) 2011-05-30
CA2275596A1 (en) 1998-07-02
RS49882B (sr) 2008-08-07
MY118015A (en) 2004-08-30
CZ229299A3 (cs) 1999-09-15
JP2009197022A (ja) 2009-09-03
IN186976B (cg-RX-API-DMAC7.html) 2001-12-22
ES2251038T3 (es) 2006-04-16
CO5070688A1 (es) 2001-08-28
UA60324C2 (uk) 2003-10-15
DK0950050T3 (da) 2006-01-23
ZA9711576B (en) 1998-06-25
EP0950050B1 (fr) 2005-10-26
HK1024002A1 (en) 2000-09-29
HRP970699A2 (en) 1998-10-31
SK82899A3 (en) 1999-12-10
EE04188B1 (et) 2003-12-15
TR199901363T2 (xx) 1999-08-23
RU2192416C2 (ru) 2002-11-10
YU28999A (sh) 2003-01-31
SI0950050T1 (sl) 2006-04-30
NO993076L (no) 1999-06-22
DE69734460T2 (de) 2006-07-06
WO1998028271A1 (fr) 1998-07-02
CN1241180A (zh) 2000-01-12
HRP970699B1 (en) 2007-03-31
KR20000069504A (ko) 2000-11-25
NO312364B1 (no) 2002-04-29
ATE307802T1 (de) 2005-11-15
IL129938A0 (en) 2000-02-29
IS5076A (is) 1999-06-10
JP2001507012A (ja) 2001-05-29
AU736697B2 (en) 2001-08-02
SK285088B6 (sk) 2006-06-01
NZ336130A (en) 2001-01-26
IS2357B (is) 2008-04-15
DZ2383A1 (fr) 2002-12-28
CZ296689B6 (cs) 2006-05-17
HUP0001387A3 (en) 2002-03-28
BR9714081A (pt) 2000-05-09

Similar Documents

Publication Publication Date Title
CN1187367C (zh) 具有麻醉剂活性的3α-羟基-3β-甲氧基甲基-21-杂环取代的类固醇
CN1090935C (zh) 哌啶子基烷醇化合物的药物组合物
HK1211032A1 (en) Solid forms of a selective cdk4/6 inhibitor
JP2009035535A (ja) バゼドキシフェンアセテートの結晶多形
CN1582278A (zh) 多晶型rimonabant,其制备方法及含有它的药物组合物
JP2013014584A (ja) アゴメラチンの新規な共結晶、その調製のための方法及びそれを含む医薬組成物
AU2001272872B2 (en) Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro -2-naphthyl)-4-morpholinobenzamide
CN1129580C (zh) 结晶四氢吡啶衍生物的方法及所得晶形
WO2015176591A1 (zh) 贝曲西班盐及其制备方法和用途
AU2001272872A1 (en) Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro -2-naphthyl)-4-morpholinobenzamide
CN1414956A (zh) 作为mip抑制剂的经取代的哌嗪衍生物
JP2003516414A (ja) より高い溶解速度を示すエプレレノン結晶形
CN1114592C (zh) 奥沙奈丹的晶型
US20040063782A1 (en) Bicalutamide forms
JP2002505254A (ja) パロキセチン塩
CN1520403A (zh) 托拉塞米的新颖多晶型物v
CN1305474A (zh) 帕罗西汀马来酸盐
CN1140510C (zh) (r)-3-[[(4-氟苯基)磺酰基]氨基]-1,2,3,4-四氢-9h-咔唑-9-丙酸(拉马曲班)的热力学稳定形式
HK1024002B (en) Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms
CN1374866A (zh) N-甲基-N-(3-{3-[2-噻吩基羰基]-吡唑-[1,5-α]-嘧啶-7-基}苯基)乙酰胺的多晶型物和含有该物质的组合物以及相关的制备方法
HU213410B (en) Method for producing a novel physical modification of a carbamoylindole derivative and the pharmaceutical compositions comprising it
CN1812767A (zh) 一种制备药用有效成分晶体的方法以及由该方法获得的晶体和晶体在药剂制备中的应用
EP1713769B1 (en) Amorphous tamsulosin hydrochloride
WO2025198486A1 (en) Process for preparing a pyrazolo[1,5-a]pyrimidinyl carboxamide compound
CN1443185A (zh) 药用的5-(4-(2-(n-甲基-n-(2-吡啶基)氨基)乙氧基)苄基)噻唑烷-2,4-二酮氢碘化物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SANOFI. AVENTIS CO., LTD.

Free format text: FORMER NAME OR ADDRESS: SANOFI SYNTHESIZING LABORATORY

CP01 Change in the name or title of a patent holder

Address after: Paris France

Patentee after: SANOFI-AVENTIS

Address before: Paris France

Patentee before: SANOFI-SYNTHELABO

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20031203

Termination date: 20111223